Potential biomarkers for kidney cancer
Immunotherapy medicines have dramatically changed the way advanced (metastatic) kidney [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Treatment of rare subtypes of kidney cancer
At the International Kidney Cancer Symposium (IKCS) in North America [...]
Biomarkers for immunotherapy outcomes for kidney cancer
This review in the journal Cereus is very technical, but [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
COVID-19 and cancer: Immunotherapy and immunosuppressive cancer therapies
This review summarises the outcomes of people with COVID-19 taking [...]
Delayed nephrectomy after immunotherapy for metastatic kidney cancer
Neoadjuvant therapy is the treatment given as a first step [...]
